Nabsys | GenomeWeb

Nabsys

At a workshop organized by the Genome in a Bottle consortium last month, Nabsys presented its human genome maps for the first time.

After closing its doors last September, Nabsys has resumed operations, refocusing on its core technology.

2.0 Time

Former CEO Barrett Bready has purchased the recently shuttered Nabsys for $500,000 and the assumption of $100,000 in debt, according to GoLocalProv.

According to local news reports, the company recently closed its facility in Providence, Rhode Island.

Nabsys CEO Steve Lombardi and CSO Tony Shuber spoke with GenomeWeb at last week's JP Morgan conference in San Francisco. 

The companies will combine Nabsys' technology to identify the structural variants with Ariana's clinical data analysis tools.

NabSys has been awarded

This article was originally published Nov. 3.
NEW YORK (GenomeWeb) – Following the recent appointments of a new CEO and CSO, Nabsys is shifting its strategy toward developing a platform for clinical applications, in particular structural variation analysis of cancer genomes.

Quest Diagnostics has elected Jeffrey Leiden to its Board of Directors. Leiden is the chairman, president, and CEO of Vertex Pharmaceuticals.

Nabsys said that Anthony Shuber has joined the company as vice president and chief scientific officer. He comes to Nabsys from Ignyta, an oncology precision medicine firm, where he served as chief technology officer.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.